Media coverage about Sonoma Pharmaceuticals (NASDAQ:SNOA) has been trending somewhat negative this week, according to Accern. Accern rates the sentiment of press coverage by monitoring more than twenty million blog and news sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Sonoma Pharmaceuticals earned a news sentiment score of -0.15 on Accern’s scale. Accern also gave news headlines about the company an impact score of 46.2190378956912 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the company’s share price in the next few days.

Here are some of the news headlines that may have effected Accern’s rankings:

A number of research firms have issued reports on SNOA. Zacks Investment Research upgraded shares of Sonoma Pharmaceuticals from a “hold” rating to a “buy” rating and set a $6.25 target price for the company in a research note on Wednesday, January 10th. Maxim Group lifted their target price on shares of Sonoma Pharmaceuticals from $10.00 to $11.00 and gave the company a “buy” rating in a research note on Friday, November 10th. Finally, Benchmark began coverage on shares of Sonoma Pharmaceuticals in a research note on Thursday, December 28th. They issued a “speculative buy” rating and a $10.00 target price for the company.

Sonoma Pharmaceuticals (NASDAQ:SNOA) traded up $0.18 during midday trading on Tuesday, reaching $4.45. 9,911 shares of the company’s stock were exchanged, compared to its average volume of 25,050. The company has a debt-to-equity ratio of 0.01, a current ratio of 5.37 and a quick ratio of 4.56. The firm has a market capitalization of $19.03, a PE ratio of -1.54 and a beta of 0.97. Sonoma Pharmaceuticals has a 1 year low of $4.16 and a 1 year high of $8.25.

TRADEMARK VIOLATION WARNING: This piece was originally posted by The Cerbat Gem and is owned by of The Cerbat Gem. If you are accessing this piece on another domain, it was copied illegally and reposted in violation of United States & international copyright laws. The correct version of this piece can be read at https://www.thecerbatgem.com/2018/02/13/somewhat-critical-media-coverage-somewhat-unlikely-to-affect-sonoma-pharmaceuticals-snoa-stock-price.html.

About Sonoma Pharmaceuticals

Sonoma Pharmaceuticals, Inc, formerly Oculus Innovative Sciences, Inc, is a specialty pharmaceutical company that develops and markets solutions for the treatment of dermatological conditions and advanced tissue care. The Company’s product portfolio consists of dermatology and advanced tissue care products based upon its technologies, such as Microcyn and Lipogrid.

Insider Buying and Selling by Quarter for Sonoma Pharmaceuticals (NASDAQ:SNOA)

Receive News & Ratings for Sonoma Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sonoma Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.